Aetna — Q3 2018 Earnings Presentation
14 slides from Aetna's earnings presentation, Nov 6, 2018
Slide 1: Third Quarter 2018 Earnings Conference Call
Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-6 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc. Commission File No.: 001-16095 Date: November 6, 2018 Third Quarter 2018 Earnings Conference Call Larry
Slide 2: Important Information
Important Information No Offer or Solicitation This communication is for informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of an offer to subscribe for, buy or sell or an invitation to subscribe for, buy or sell any secur
Slide 3: Important Information: Cautionary Statement Regarding Forward-Looking Statements
Important Information Cautionary Statement Regarding Forward-Looking Statements The Private Securities Litigation Reform Act of 1995 (the "Reform Act") provides a safe harbor for forward-looking statements made by or on behalf of CVS Health or Aetna. This communication may contain forward-looking st
Slide 4: Important Information
Important Information In addition, this communication may contain forward-looking statements regarding CVS Health's or Aetna's respective businesses, financial condition and results of operations. These forward-looking statements also involve risks, uncertainties and assumptions, some of which may n
Slide 5: Forward-looking Statements
Forward-looking Statements This presentation contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements reflect our current views related to our future financial performance, future events and industry and market conditions. Forward-lookin
Slide 6: Aetna Update
Aetna Update 6 (c) 2018 CVSHealth CVSHealth
Slide 7: Progress on Aetna Transaction
Progress on Aetna Transaction Regulatory Update Received approval from the Department of Justice on October 10th Final stages of state approval process: received 23 of 28 state approvals needed, including CT, our lead regulator Expect to close prior to Thanksgiving Immediate priorities of integratio
Slide 8: Longer-Term Value Creation
Longer-Term Value Creation Targeting substantial savings through specific portfolio of products & services Better management of five common chronic conditions by building upon near-term medical cost savings through tighter integration of pharmacy and medical claims, the rich clinical dataset we will
Slide 9: Three Priorities Guide How Health Care Consumer Engagement is Transformed
Three Priorities Guide How Health Care Consumer Engagement is Transformed ... Be Local Make it Simple Improve Health ... and guide our strategies for medical cost savings Common Chronic Disease Management Readmission Prevention Site of Care Management Optimize Primary Care Complex Chronic Disease Ma
Slide 10: CVS Health is Uniquely Positioned to Address Medical Cost Savings Opportunities
CVS Health is Uniquely Positioned to Address Medical Cost Savings Opportunities Digital Capabilities Data, Analytics and Technology Community-Based Assets Partnerships Unmatched connections to the consumer ... at the center 10 (c) 2018 CVSHealth CVSHealth
Slide 11: Multiple Levers of Value Creation Allow CVS Health to Accelerate Enterprise Growth
Multiple Levers of Value Creation Allow CVS Health to Accelerate Enterprise Growth Value Creation Levers Medical Cost Savings Membership Growth Increased Customer Satisfaction and Retention Expanded Customer Value Through CVS Assets Open Platform Allows for Broad Partnerships Value creation to deliv
Slide 12: 2018 Guidance
2018 Guidance 12 (c) 2018 CVSHealth CVSHealth
Slide 13: Guidance: 2018 Full-year Enterprise Outlook
Guidance: 2018 Full-year Enterprise Outlook Full-year 2018 Net Revenue Growth 1.5% to 2.5% Retail Same-Store Adjusted Scripts (1) (2) 8.25% to 9.25% PSS Total Adjusted Claims (2) 1.88 billion to 1.90 billion Adjusted Operating Profit Growth (0.75%) to 0.75% Adjusted EPS Growth $6.98 to $7.08 18.25%
Slide 14: Impacts From the Close of Aetna Transaction
Impacts From the Close of Aetna Transaction From a non-GAAP perspective, upon closing, the net interest expense associated with the deal-related debt raised in March will be included in the non-GAAP figures We expect to issue approximately 285 million shares There will be a slight increase in the co